• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Keppra (levetiracetam) Tablets, Extended Release Tablets, Oral Solution and Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

March 2014

Summary View

ADVERSE REACTIONS

Postmarketing Experiences
  • muscle weakness and panic attack